

Robert A. Gross, MD, PhD, FAAN, Editor-in-Chief, *Neurology*<sup>®</sup>



## Notable in *Neurology* this week

This issue features an article that explores whether medication contributes to the increased risk of seizures in patients with attention-deficit/hyperactivity disorder; another reports midlife insulin resistance as an independent risk factor for brain amyloid accumulation. A featured Views & Reviews article discusses recent advances in the use of the head impulse test for central vestibular disorders.

## Articles

### Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study


This article provides insight into the increased risk for patients with epilepsy during transportation (car, bicycle, and pedestrian) independent of antiepileptic drug (AED) medication. The authors' within-individual analyses regarding AED medication allowed adjustment for potential unmeasured, but important, confounders. The study's findings can help educate patients about risks and preventive measures.

Page 590

From editorialists Krumholz and Berg: "Transportation for people with epilepsy has come a long way. There is still far to go; the study by Sundelin et al.<sup>6</sup> brings welcomed critical information about the risks faced and posed by people with epilepsy as they move through their everyday lives."

Page 583

### Regional oxygen extraction predicts border zone vulnerability to stroke in sickle cell disease



The border zone (BZ), a blood flow nadir, is vulnerable to stroke in sickle cell disease. Using MRI, the authors found elevation of oxygen extraction fraction and decreased oxygen utilization in the BZ, which colocalized with infarct density. Physiology of the BZ may predict stroke risk in sickle cell disease.

Page 593

From editorialists Stotesbury et al.: "The identification of novel, noninvasive imaging biomarkers potentially sensitive to local vascular compromise in children holds promise for identifying those most at risk for future trials of early treatment intervention in SCA."

Page 585

## MORE ONLINE

### 🎧 Editor's Summary

Audio summary of highlighted articles.

[NPub.org/edsum](https://www.neurology.org/edsum)

Continued

## Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin

This survey study explored the characteristics and outcomes of direct oral anticoagulant (DOAC)-associated nontraumatic intracerebral hemorrhages. Propensity score analysis revealed that DOAC-treated patients had milder hemorrhages, lower hematoma expansion frequencies, and lower mortality rates than those treated with warfarin. The authors recommend DOACs as first-line drugs when treating atrial fibrillation.

Page 594

## Retinal signs and 20-year cognitive decline in the Atherosclerosis Risk in Communities Study

Microvascular disease is preventable, yet the extent of its contribution to cognitive decline is unknown. In persons aged 50–71, retinal signs (retinopathy,  $\geq 1$  retinal hemorrhages or microaneurysms) were associated with an accelerated 20-year cognitive decline. Routine ophthalmoscopy may suggest the need for closer vascular risk factor control than otherwise indicated.

Page 596

NB: “Dilation lag in Horner syndrome can be measured with a diagnostic imaging system,” p. 618. To check out other NeuroImages, point your browser to [Neurology.org/N](http://Neurology.org/N). At the end of the issue, check out the Resident & Fellow Child Neurology article discussing the presentation of type 1 sialidosis due to a mutation in the NEU1 gene. This week also includes a Reflections: Neurology and the Humanities short story titled “The circus of life.”

### NEW EPISODE



March 27, 2018

### IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients (see the September 2017 issue of *Neurology*<sup>®</sup> *Neuroimmunology & Neuroinflammation*)

- 1) Featured Article: IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients
- 2) What's Trending: Recent changes to Maintenance of Certification Requirements

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 27, 2018, issue of *Neurology*. In the first segment, Dr. Stacey Clardy talks with Dr. Andrew McKeon about his *Neurology: Neuroimmunology & Neuroinflammation* paper describing IgLON5 autoimmunity. For the “What's Trending” segment, Dr. Jason Crowell speaks with Luana Ciccarelli and Amanda Napoles on regulatory updates in coding and reimbursement, MACRA, and tips for private practitioners on participating in the Quality Payment Program.

Disclosures can be found at [Neurology.org/podcast](http://Neurology.org/podcast).

**No CME this week:** Interviews based on articles from *Neurology*<sup>®</sup> *Clinical Practice*, *Neurology*<sup>®</sup> *Genetics*, and *Neurology: Neuroimmunology & Neuroinflammation* are excluded from the CME program.

# Neurology<sup>®</sup>

**Spotlight on the March 27 issue**

Robert A. Gross

*Neurology* 2018;90;579-580

DOI 10.1212/WNL.0000000000005220

**This information is current as of March 26, 2018**

**Updated Information & Services**

including high resolution figures, can be found at:  
<http://n.neurology.org/content/90/13/579.full>

**Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
[http://www.neurology.org/about/about\\_the\\_journal#permissions](http://www.neurology.org/about/about_the_journal#permissions)

**Reprints**

Information about ordering reprints can be found online:  
<http://n.neurology.org/subscribers/advertise>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

